ALDX – Aldeyra Therapeutics, Inc.
Float Short %
9.43
Margin Of Safety %
Put/Call OI Ratio
0.78
EPS Next Q Diff
-0.02
EPS Last/This Y
0.34
EPS This/Next Y
0.99
Price
4.95
Target Price
9.67
Analyst Recom
1
Performance Q
0.81
Upside
-609.1%
Beta
0.97
Ticker: ALDX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | ALDX | 5.2 | 0.40 | 0.64 | 17967 |
| 2026-01-26 | ALDX | 5.22 | 0.41 | 1.15 | 18676 |
| 2026-01-27 | ALDX | 5.55 | 0.42 | 0.12 | 18901 |
| 2026-01-28 | ALDX | 5.41 | 0.40 | 0.05 | 19548 |
| 2026-01-29 | ALDX | 5.33 | 0.40 | 0.26 | 19832 |
| 2026-01-30 | ALDX | 5.36 | 0.40 | 1.06 | 19846 |
| 2026-02-02 | ALDX | 5.44 | 0.41 | 5.20 | 20237 |
| 2026-02-03 | ALDX | 5.41 | 0.49 | 0.83 | 21443 |
| 2026-02-05 | ALDX | 5.1 | 0.49 | 0.14 | 21995 |
| 2026-02-09 | ALDX | 5.56 | 0.45 | 0.16 | 22983 |
| 2026-02-10 | ALDX | 5.49 | 0.45 | 2.28 | 23139 |
| 2026-02-11 | ALDX | 5.34 | 0.48 | 6.32 | 23980 |
| 2026-02-12 | ALDX | 5.27 | 0.74 | 1.61 | 28365 |
| 2026-02-13 | ALDX | 5.45 | 0.80 | 8.25 | 28888 |
| 2026-02-17 | ALDX | 5.16 | 0.86 | 1.59 | 30304 |
| 2026-02-18 | ALDX | 5.03 | 0.86 | 3.06 | 30883 |
| 2026-02-19 | ALDX | 5.09 | 0.79 | 0.67 | 30275 |
| 2026-02-20 | ALDX | 4.94 | 0.78 | 0.90 | 30615 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | ALDX | 5.20 | 45.7 | - | -0.60 |
| 2026-01-26 | ALDX | 5.23 | 45.7 | - | -0.60 |
| 2026-01-27 | ALDX | 5.54 | 45.7 | - | -0.60 |
| 2026-01-28 | ALDX | 5.41 | 45.7 | - | -0.60 |
| 2026-01-29 | ALDX | 5.32 | 45.7 | - | -0.60 |
| 2026-01-30 | ALDX | 5.37 | 45.7 | - | -0.60 |
| 2026-02-02 | ALDX | 5.44 | 45.7 | - | -0.60 |
| 2026-02-03 | ALDX | 5.42 | 45.7 | - | -0.60 |
| 2026-02-04 | ALDX | 5.23 | 45.7 | - | -0.60 |
| 2026-02-05 | ALDX | 5.10 | 45.7 | - | -0.60 |
| 2026-02-06 | ALDX | 5.53 | 45.7 | - | -0.60 |
| 2026-02-09 | ALDX | 5.55 | 46.3 | - | -0.60 |
| 2026-02-10 | ALDX | 5.49 | 46.3 | - | -0.60 |
| 2026-02-11 | ALDX | 5.34 | 46.3 | - | -0.60 |
| 2026-02-12 | ALDX | 5.27 | 46.3 | - | -0.60 |
| 2026-02-13 | ALDX | 5.21 | 46.3 | - | -0.60 |
| 2026-02-17 | ALDX | 5.16 | 46.3 | - | -0.60 |
| 2026-02-18 | ALDX | 5.03 | 46.3 | - | -0.60 |
| 2026-02-19 | ALDX | 5.09 | 46.3 | - | -0.60 |
| 2026-02-20 | ALDX | 4.95 | 46.3 | - | -0.60 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | ALDX | -0.99 | 7.28 | 8.51 |
| 2026-01-26 | ALDX | -0.99 | 7.29 | 8.51 |
| 2026-01-27 | ALDX | -0.99 | 7.29 | 8.51 |
| 2026-01-28 | ALDX | -0.99 | 7.29 | 8.76 |
| 2026-01-29 | ALDX | -0.99 | 7.29 | 8.76 |
| 2026-01-30 | ALDX | -0.99 | 7.29 | 8.76 |
| 2026-02-02 | ALDX | -0.99 | 7.46 | 8.76 |
| 2026-02-03 | ALDX | -0.99 | 7.46 | 8.76 |
| 2026-02-04 | ALDX | -0.99 | 7.46 | 8.76 |
| 2026-02-05 | ALDX | -0.99 | 7.46 | 8.76 |
| 2026-02-06 | ALDX | -0.99 | 7.46 | 8.76 |
| 2026-02-09 | ALDX | -0.99 | 6.99 | 8.76 |
| 2026-02-10 | ALDX | -0.99 | 6.99 | 8.76 |
| 2026-02-11 | ALDX | -0.99 | 6.99 | 9.02 |
| 2026-02-12 | ALDX | -0.99 | 6.99 | 9.02 |
| 2026-02-13 | ALDX | -0.99 | 6.99 | 9.02 |
| 2026-02-17 | ALDX | 0.00 | 13.29 | 9.43 |
| 2026-02-18 | ALDX | 0.00 | 13.29 | 9.43 |
| 2026-02-19 | ALDX | 0.00 | 13.29 | 9.43 |
| 2026-02-20 | ALDX | 0.00 | 13.29 | 9.43 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.13
Avg. EPS Est. Current Quarter
-0.15
Avg. EPS Est. Next Quarter
-0.15
Insider Transactions
Institutional Transactions
13.29
Beta
0.97
Average Sales Estimate Current Quarter
24
Average Sales Estimate Next Quarter
Fair Value
Quality Score
10
Growth Score
23
Sentiment Score
40
Actual DrawDown %
69
Max Drawdown 5-Year %
-90.4
Target Price
9.67
P/E
Forward P/E
46.4
PEG
P/S
P/B
6.05
P/Free Cash Flow
EPS
-0.72
Average EPS Est. Cur. Y
-0.6
EPS Next Y. (Est.)
0.39
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.44
Return on Equity vs Sector %
-116.7
Return on Equity vs Industry %
-99.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Aldeyra Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 8
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
stock quote shares ALDX – Aldeyra Therapeutics, Inc. Stock Price stock today
news today ALDX – Aldeyra Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALDX – Aldeyra Therapeutics, Inc. yahoo finance google finance
stock history ALDX – Aldeyra Therapeutics, Inc. invest stock market
stock prices ALDX premarket after hours
ticker ALDX fair value insiders trading